反応式
[C:1]([C:3]1[C:8]([NH:9][C:10]2[O:14][N:13]=[C:12]([C:15]3[CH:20]=[CH:19][CH:18]=[CH:17][CH:16]=3)[CH:11]=2)=[CH:7][C:6]([NH:21][C@H:22]([CH2:26][CH:27]2[CH2:29][CH2:28]2)[C:23]([NH2:25])=[O:24])=[C:5]([F:30])[CH:4]=1)#[N:2].[OH-].[Na+].OO.CC(O)=[O:37]>CCO.CS(C)=O>[NH2:25][C:23](=[O:24])[C@H:22]([NH:21][C:6]1[C:5]([F:30])=[CH:4][C:3]([C:1]([NH2:2])=[O:37])=[C:8]([NH:9][C:10]2[O:14][N:13]=[C:12]([C:15]3[CH:20]=[CH:19][CH:18]=[CH:17][CH:16]=3)[CH:11]=2)[CH:7]=1)[CH2:26][CH:27]1[CH2:28][CH2:29]1参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
To a solution of (R)-2-(4-cyano-2-fluoro-5-(3-phenylisoxazol-5-ylamino)phenylamino)-3-cyclopropylpropanamide (75 mg) in EtOH (1 mL) and DMSO (0.5 mL) at room temperature, aq. 1N NaOH (0.5 mL) and aq. H2O2 (50%, 0.5 mL) were added. The mixture was stirred at room temperature for 15 min. HOAc (0.5 mL) was added. After being concentrated in vacuo, the residue was purified by HPLC to give the titled compound (13 mg). MS 424.4 (M+H); UV 201.0, 244.9, 289.1 nm; t 0.668 min.
後処理
- concentrationAfter being concentrated in vacuo
- customthe residue was purified by HPLC
出典と根拠
- ORDレコード
- ord-357775f09b9a43e888d3ed59288a0a6e
- 出典データセット
- uspto-grants-2014_09
- 特許番号
- US08846928B2
関連ノート
読み込み中…